|
| 37971722 | Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial. | JAMA Oncol | 2024 |
| 36082904 | Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors. | Oncologist | 2023 |
| 37637234 | Autoimmune HLA Alleles and Neoepitope Presentation Predict Post-Allogenic Transplant Relapse. | J Immunother Precis Oncol | 2023 |
| 37046091 | Chromosomal fragile site breakage by EBV-encoded EBNA1 at clustered repeats. | Nature | 2023 |
| 37046089 | Extrachromosomal DNA in the cancerous transformation of Barrett's oesophagus. | Nature | 2023 |
| 37075754 | KaryoCreate: A CRISPR-based technology to study chromosome-specific aneuploidy by targeting human centromeres. | Cell | 2023 |
| 37132280 | LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics. | Cancer Med | 2023 |
| 36994197 | Cancer, more than a "COVID-19 co-morbidity". | Front Oncol | 2023 |
| 36721313 | Deep learning-based pathology image analysis predicts cancer progression risk in patients with oral leukoplakia. | Cancer Med | 2023 |
| 36694946 | Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population. | Mol Oncol | 2023 |
| 36597662 | Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort. | Cancer | 2023 |
| 36596361 | Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-focal adhesion kinase signaling circuitry. | J Biol Chem | 2023 |
| 34426440 | Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response. | Clin Cancer Res | 2022 |
| 35603292 | Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. | Commun Med (Lond) | 2022 |
| 36138116 | Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy. | NPJ Precis Oncol | 2022 |
| 36134663 | AI-assisted discovery of an ethnicity-influenced driver of cell transformation in esophageal and gastroesophageal junction adenocarcinomas. | JCI Insight | 2022 |
| 36129397 | Proteogenomic analysis of cancer aneuploidy and normal tissues reveals divergent modes of gene regulation across cellular pathways. | Elife | 2022 |
| 36395141 | Somatic 9p24.1 alterations in HPV<sup>-</sup> head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity. | Proc Natl Acad Sci U S A | 2022 |
| 36252553 | JAK: Not Just Another Kinase. | Mol Cancer Ther | 2022 |
| 33511883 | Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial. | Nutr Cancer | 2022 |
| 34705295 | Primary cutaneous anaplastic large-cell lymphoma with aberrant cytokeratin expression: An unusual mimicker of poorly differentiated carcinomas. | J Cutan Pathol | 2022 |
| 34255745 | Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions. | JCI Insight | 2021 |
| 34857015 | Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden. | J Hematol Oncol | 2021 |
| 34708934 | Asymptomatic detection of SARS-CoV-2 among cancer patients receiving infusional anti-cancer therapy. | Cancer Med | 2021 |
| 34607609 | Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. | Genome Med | 2021 |
| 34625409 | Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. | Cancer Prev Res (Phila) | 2021 |
| 33989559 | Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. | Lancet Oncol | 2021 |
| 33952700 | Immune evasion in HPV<sup>-</sup> head and neck precancer-cancer transition is driven by an aneuploid switch involving chromosome 9p loss. | Proc Natl Acad Sci U S A | 2021 |
| 31361623 | A Model-Based Cost-Effectiveness Analysis of an Exercise Program for Lung Cancer Survivors After Curative-Intent Treatment. | Am J Phys Med Rehabil | 2020 |
| 31965306 | Effects of curative-intent lung cancer therapy on functional exercise capacity and patient-reported outcomes. | Support Care Cancer | 2020 |
| 31782524 | Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. | Int J Cancer | 2020 |
| 32066498 | The paradox of cancer genes in non-malignant conditions: implications for precision medicine. | Genome Med | 2020 |
| 32941797 | Shining Light on the COVID-19 Pandemic: A Vitamin D Receptor Checkpoint in Defense of Unregulated Wound Healing. | Cell Metab | 2020 |
| 32949172 | Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience. | Oncologist | 2020 |
| 33009371 | Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. | Nat Commun | 2020 |
| 32506665 | The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial. | Prostate | 2020 |
| 32251345 | Author Correction: Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan. | Sci Rep | 2020 |
| 30420444 | Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial. | Clin Cancer Res | 2019 |
| 31676588 | Targeting mTOR in Head and Neck Cancer-Response. | Clin Cancer Res | 2019 |
| 31320401 | Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. | Mol Cancer Ther | 2019 |
| 31292160 | Metformin Inhibits Progression of Head and Neck Squamous Cell Carcinoma by Acting Directly on Carcinoma-Initiating Cells. | Cancer Res | 2019 |
| 31405947 | Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. | Cancer Immunol Res | 2019 |
| 30894372 | 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer. | Cancer Res | 2019 |
| 31032472 | Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. | JCO Precis Oncol | 2019 |
| 31058253 | Revisiting Epidermal Growth Factor Receptor (<i>EGFR</i>) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. | JCO Precis Oncol | 2019 |
| 30718357 | Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer. | Cancer Res | 2019 |
| 29228205 | Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. | Carcinogenesis | 2018 |
| 29985391 | Assembly and activation of the Hippo signalome by FAT1 tumor suppressor. | Nat Commun | 2018 |
| 29902298 | Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. | JAMA Oncol | 2018 |
| 29980517 | The Ashitaba (<i>Angelica keiskei</i>) Chalcones 4-hydroxyderricin and Xanthoangelol Suppress Melanomagenesis By Targeting BRAF and PI3K. | Cancer Prev Res (Phila) | 2018 |